An innovative service company focusing on the field of drug quality control

News

Contact Us

You are here:Home >> News >> Company News

Company News

SZEB supply drug impurity of Avatrombopag

Time:2022-12-16 Views:304
Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors
The FDA approved a supplemental New Drug Application (sNDA) for avatrombopag (Doptelet) as a treatment for adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior therapy.
SZEB provide the impurities of Avatrombopag -related impurities,Discover all our products through our official website (https://www.ex-biotech.com/), and get in touch if you have any questions about how we can help support your work. Email:sale@ex-biotech.com.
The following are some of the impurities of Avatrombopag:
  • Previous:Lincomycin Impurity  2024/11/18
  • Next:SZEB supply drug impurity of Crisaborole  2022/12/01